The cytosolic hyaluronic acid level defines some clinical-biological properties of CD44v5-positive infiltrating ductal carcinomas of the breast;La concentración de ácido hialurónico citosólico define ciertas propiedades clinicobiológicas del carcinoma ductal infiltrante de mama CD44v5 positivo

Medicina Clinica

Volumn 115, Issue 6, 2000, Pages 205-207

  Ruibal, Álvaro ^a,b,f   Arias, José Ignacio ^b   Carmen Del Rio M ^c   San Román, Juan Manuel ^d   Lapeña, Gregoria ^a   Schneider, José ^b,e   Tejerina, Armando ^b,e  

^a Fundocion Jimenez Diaz   (Spain)

^b Hospital Monte del Naranco   (Spain)

^c Hospital de Barbanza   (Spain)

^d Cirugía Exp Hosp Univ   (Spain)

^e Centro de Patologia de la Mama   (Spain)

^f Servicio de Medicina Nuclear   (Spain)

Author keywords

Breast; CD44v5; Clinical biological aspects; Cytosol; Hyaluronic acid; Infiltrating ductal carcinomas

Indexed keywords

CATHEPSIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; HERMES ANTIGEN; HYALURONIC ACID; PROGESTERONE RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; CYTOSOL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; RADIOASSAY; RADIOIMMUNOASSAY;

ADULT; ANTIGENS, CD44; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CATHEPSINS; CYTOSOL; FEMALE; HUMANS; HYALURONIC ACID; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; RADIOIMMUNOASSAY; RADIOLIGAND ASSAY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 85046527925     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71510-7     Document Type: Article

References (40)

1. Herrera Gayol A, Jothy S. CD44 modulates HS578T human breast cancer cell adhesion, migration and invasiveness. Exp Mol Pathol 1999; 66: 99-108.
2. Till KJ, Zuzel M, Cawley JC. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Rs 1999; 59: 4419-4426.
3. Kainz C, Tempfer C. CD44 as a differentiation marker and metastasis promoter in gynecological malignancies. Cancer J 1997; 10: 306-309.
4. Ladeda V, Aguirre Chiso JA, Bal de Kier Joffer E. Function and expression of CD44 during spreading, migration, and invasion of murine carcinoma cells. Exp Cell Res 1998; 242: 515-527.
5. Sinn HP, Heider KH, Skroch-Angel P, Von Minckwitz G, Kaufmann M, Herrlich P et al. Human mammary carcinomas express homologues of rat metastasis associated variants of CD44. Breast Cancer Res Treat 1995; 363: 307-313.
6. Regidor PA, Callies R, Regidor M, Gunther U, Zoller M, Schindler AE. Expressions of the CD44 variant isoforms 6 and 4/5 in breast cancer. Correlation with established prognostic parameters. Arch Gynecol Obstet 1996; 258: 123-135.
7. Yagan LR, Quinn B. CD44 expression in astrocytic tumors. Mod Pathol 1997; 10: 1239-1246.
8. Yamamich K, Uehara Y, Kitamura N, Nakane Y, Hioki K. Increased expressions of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer 1998; 79: 256-262.
9. Rodriguez Rodríguez L, Sancho Torres I, Leakey P, Gibbon DG, Comerci JT, Ludlow JW et al. CD44 splice variant expression in clear cell carcinoma of the ovary. Gynecol Oncol 1998; 71: 223-229.
10. Kondo K, Miyoshi T, Hino N, Shimizu E, Masuda N, Takada M et al. High frequency expressions of CD44 standard and variant froms in non-small cell lung cancer, but not in small cell lung cancers. J Surg Oncol 1998; 69: 128-136.
11. Victor R, Chauzy C, Girard N, Gioanni J, D'Anjou J, Stora de Novion H et al. Human breast-cancer metastasis formation in a nude-mouse model: studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. Int J Cancer 1999: 82; 77-83.
12. Yu Q, Stamenkovic I. Localization of matrix matlloproteinase 9 to the cell surface provides a mechanisn for CD44 mediated tumor invasion. Genes Dev 1999; 13: 35-48.
13. Hefler L, Tempfer C, Haeusler G, Kucera E, Mayerhofer K, Seilllinger R et al. Cytosol concentrations of CD44 isoforms in breast cancer tissue. Int J Cancer 1998; 79: 541-545.
14. Tempfer C, Losch A, Heinzl H, Hausler G, Hanzal E, Kolbl H et al. Prognostic value of immunonistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur J Cancer 1996; 32: 2023-2025.
15. Nuñez MI, Arias JL, Del Rio MC, Martinez MI, Alba A, A'lende MT et al. Estudio de las concentraciones de CD44v5 en la membrana celular de carcinomas ductales infiltrantes de mama. Resultados preliminares. Rev Senol Pat Mamaria 1997; 10: 175-180.
16. Nuñez MI, Arias JL, Del Río MC, Martinez MI, Alba A, Allende MT et al. Cell surface CD44v5 levels correlate with progresterone receptos and a tumor size > 2 cm in infiltrating ductal carcinomas of the breast. Int J Biol Markers 1996; 11: 220-222.
17. Culty M, Shizari M, Thopmson EW, Underhill CB. Binding and degradation of hyaluronan by human breast cancer cell lines expressiong different forms of CD44: correlation with invasive potential. J Cell Physiol 1994; 160: 275-286.
18. Yu Q, Tool BP, Stamekovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 1997; 186: 1985-1996.
19. Ruibal A, Schneider J, Arias JI, Del Rio MC, Tejerina A. Membrane hyaluronic acid in breast cancer. Definition of biologically different subpopulations among CD44v5-positive cases. Breast Cancer Res Treat 1999; 57: 138.
20. Masuda M, Takano Y, Iki M, Makiyama K, Noguchi S, Hosaka M. Expression and prognostic value of CD44 isoforms in transitional cell carcinoma of renal pelvis and ureter. J Urol 1999; 161: 805-808.
21. Saegusa M, Hashimura M, Machida D, Okayasu I. Down regulation of CD44 standard and variant isoforms during the developement and progression of uterine cervical tumors. J Pathol 1999; 187: 173-183.
22. Lu D, Tawfik O, Pantanzis C, Hobart W, Chapman J, Ockowski K Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression. Gynecol Oncol 1999; 75: 84-90.
23. Gilcrease MZ, Guzman Paz M, Niehans G, Cherwitz D, McCarthy JB, Albores-Saavedra J. Correlation of CD44s expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 1999; 86: 232-236.
24. Guriec N, Gairad B, Marcellin L, Wilk A, Calderoli H, Renaud R et al. CD44 isoforms with exon v6 and metastasis of primary NOMO breast carcinomas. Breast Cancer Res Treat 1997: 44: 261-268.
25. Schneider J, Pollan M, Ruibal A, Jiménez E, Lucas AR, Sánchez J et al. Histologic grade, Ki67 and CD44 are predictors of axillary lymoh node invasion in early (T1) breast cancer Tumor Biol 1999; 20: 319-330
26. Gunia S, Hussein S, Radu DL, Putz KM, Breyer R, Hecker H et al. CD44s-targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma. Clin Exp Metastasis 1999; 17: 221-230.
27. Kaufmann M, Heider KH, Sinn HP, Von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and lenght survival. Lancet 1995; 345: 615-619.
28. Foekens JA, Dall P, Klijn JG, Skroch-Angel P, Claassen CJ, Look MP et al. Prognostic value of CD44 variant expression in primary breast cancer. Int J Cancer 1999; 84: 209-215.
29. Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ et al. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer 1996; 78: 14611469.
30. Knupfer MM, Poppenborg H, Hotfilder M, Kuhnel K, Wolff JE, Damula M. CD44 expression and hyaluronic acid binding of malignant glioma cells. Clin Exp Metastasis 1999; 17: 71-76.
31. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experiencie from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
32. Witzig TE, Ingle JN, Cha SS, Schaid DJ, Tabery RL, Wold Le et al. DNA ploidy and the percentage of cell in S-phase as prognostic factors for women with lymph node negative breast cancer. Cancer 1994; 74: 1752-1761.
33. Foekens JA, Look MP, Bolft-de Vries J, Meijervan Gelder ME, Van Putten WL, Klijn JG. Cathepsin D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999; 79: 300-307.
34. Daidone MG, Veneroni S, Benini E, Tomasic G, Coradini D, Mastore M et al. Biological markers as indicators of responde to primary and adjuvant chemotherapy in breast cancer. Int J Cancer 1999; 84: 580-586.
35. Rella C, Coviello M, Quarante M, Paradiso A. Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer. Thromb Res 1993; 69: 209-220.
36. García Muñiz JL, Álvarez A, Fernández Llana B, Fernández Raigoso P, Allende MT, Ruibal A. Cytosolic tissue-type plammogen activator (t-PA) levels in ductal infiltrating carcinomas of the breast classified according to different clinical and biological parameters. Int J Biol Markers 1995; 10: 119-121.
37. Ruibal A, Álvares A, Fernández Llana B, Fernández Fernández M, Roiz MC, Allende MT. Cytosolic tissue-type plasminogen activator (t-PA) levels in breast tumors and hormone dependence. Role of pS2. Int J Biol Markers 1994; 9: 251-253.
38. Silvestrini R, Daidone MG, Gasparini G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 1981; 48: 974-979.
39. Rudolph P, Alm P, Hiderbrecht HJ, Bolte H, Ratjen V, Baldetorp B et al. Immunologic proliferation marker Ki-S2 as prognostic parameter in breast cancer. J Natl Cancer Inst 1999; 19: 381-384.
40. González Vela MC, Garijo MF, Fernández FA, Buelta L, Val-Bernat JF. Predictors of axillary lymph node metastases in patients with invasive breast carcinoma by a combination of classical and biological prognostic factors. Pathol Res Pract 1999; 195: 611-618.